Updates on the myo-inositol plus D-chiro-inositol combined therapy in polycystic ovary syndrome

Expert Review of Clinical Pharmacology

Volumn 7, Issue 5, 2014, Pages 623-631

  Unfer, Vittorio ^a   Porcaro, Giuseppina ^b  

^a AGUNCO Obstet and Gynecol Ctr   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

Author keywords

infertility; inositol; insulin resistance; oocyte; polycystic ovarian syndrome

Indexed keywords

ANDROGEN; DEXTRO CHIRO INOSITOL; INOSITOL; UNCLASSIFIED DRUG; VITAMIN B COMPLEX;

ANOVULATION; BLOOD LEVEL; CARDIOVASCULAR RISK; DRUG SAFETY; FEMALE INFERTILITY; HUMAN; HYPERANDROGENISM; INSULIN RESISTANCE; MENSTRUAL CYCLE; MENSTRUATION DISORDER; METABOLIC DISORDER; OOCYTE; OVARY POLYCYSTIC DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPRODUCTION; REVIEW; STEREOISOMERISM; ANIMAL; CARDIOVASCULAR DISEASES; CHEMISTRY; DRUG COMBINATION; FEMALE; PATHOPHYSIOLOGY; POLYCYSTIC OVARY SYNDROME; RISK FACTOR;

ANIMALS; CARDIOVASCULAR DISEASES; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INOSITOL; INSULIN RESISTANCE; POLYCYSTIC OVARY SYNDROME; RISK FACTORS; STEREOISOMERISM; VITAMIN B COMPLEX;

EID: 84906264515     PISSN: 17512433     EISSN: 17512441     Source Type: Journal    
DOI: 10.1586/17512433.2014.925795     Document Type: Review

References (82)

1. Clements RS Jr, Darnell B. Myo-inositol content of common foods: development of a high-myo-inositol diet. Am J Clin Nutr 1980;33(9):1954-67
2. Hooper NM. Glycosyl-phosphatidylinositol anchored membrane enzymes. Clin Chim Acta 1997;266(1):3-12
3. Di Paolo G, De Camilli P. Phosphoinositides in cell regulation and membrane dynamics. Nature 2006;443(7112):651-7
4. Chen IW, Charalampous CF. Biochemical studies on inositol. IX. D-Inositol 1-phosphate as intermediate in the biosynthesis of inositol from glucose 6-phosphate, and characteristics of two reactions in this biosynthesis. J Biol Chem 1966;241(10):2194-9
5. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature 1993;361(6410): 315-25
6. Carman GM, Henry SA. Phospholipid biosynthesis in yeast. Annu Rev Biochem 1989;58:635-69
7. Huang LC, Fonteles MC, Houston DB, et al. Chiroinositol deficiency and insulin resistance. III. Acute glycogenic and hypoglycemic effects of two inositol phosphoglycan insulin mediators in normal and streptozotocin-diabetic rats in vivo. Endocrinology 1993;132(2):652-7
8. Larner J. D-chiro-inositol-its functional role in insulin action and its deficit in insulin resistance. Int J Exp Diabetes Res 2002; 3(1):47-60
9. Larner J, Huang LC, Schwartz CF, et al. Rat liver insulin mediator which stimulates pyruvate dehydrogenase phosphate contains galactosamine and D-chiroinositol. Biochem Biophys Res Commun 1988;151(3): 1416-26
10. Downes CP. The cellular functions of myo-inositol. Biochem Soc Trans 1989; 17(2):259-68
11. Downes CP, Macphee CH. Myo-inositol metabolites as cellular signals. Eur J Biochem 1990;193(1):1-18
12. Diaz JR, de las Cagigas A, Rodriguez R. Micronutrient deficiencies in developing and affluent countries. Eur J Clin Nutr 2003; 57(Suppl 1):S70-2
13. Eisenberg F Jr, Bolden AH. Reproductive Tract as Site of Synthesis and Secretion of Inositol in the Male Rat Nature. 1964;202: 599-600
14. Ghafoorunissa Effect of dietary protein on the biosynthesis of inositol in rat testes. J Reprod Fertil 1975;42(2): 233-8
15. Lewin LM, Beer R. Prostatic secretion as the source of myo-inositol in human seminal fluid. Fertil Steril 1973;24(9): 666-70
16. Lewin LM, Yannai Y, Melmed S, Weiss M. Myo-inositol in the reproductive tract of the female rat. Int J Biochem 1982;14(2): 147-50
17. Zacchè MM, Caputo L, Filippis S, et al. Efficacy of myo-inositol in the treatment of cutaneous disorders in young women with polycystic ovary syndrome. Gynecol Endocrinol 2009;25(8):508-13
18. Matsuda M, Tsutsumi K, Kanematsu T, et al. Involvement of phospholipase C-related inactive protein in the mouse reproductive system through the regulation of gonadotropin levels. Biol Reprod 2009; 81(4):681-9
19. Goud PT, Goud AP, Van Oostveldt P, Dhont M. Presence and dynamic redistribution of type I inositol 1,4,5-trisphosphate receptors in human oocytes and embryos during in-vitro maturation, fertilization and early cleavage divisions. Mol Hum Reprod 1999;5(5): 441-51
20. Lowther KM, Weitzman VN, Maier D, Mehlmann LM. Maturation, fertilization, and the structure and function of the endoplasmic reticulum in cryopreserved mouse oocytes. Biol Reprod 2009;81(1): 147-54
21. Chiu TT, Rogers MS, Briton-Jones C, et al. Effects of myo-inositol on the in-vitro maturation and subsequent development of mouse oocytes. Hum Reprod 2003;18(2): 408-16
22. Kane MT, Norris M, Harrison RA. Uptake and incorporation of inositol by preimplantation mouse embryos. J Reprod Fertil 1992;96(2):617-25
23. Stachecki JJ, Armant DR. Transient release of calcium from inositol 1,4,5-trisphosphate-specific stores regulates mouse preimplantation development. Development 1996;122(8):2485-96
24. Colazingari S, Fiorenza MT, Carlomagno G, et al. Improvement of mouse embryo quality by myo-inositol supplementation of IVF media. J Assist Reprod Genet 2014;31(4): 463-9
25. Chiu TT, Rogers MS, Law EL, et al. Follicular fluid and serum concentrations of myo-inositol in patients undergoing IVF: relationship with oocyte quality. Hum Reprod 2002;17(6):1591-6
26. Huang C, Liang NC. Increase in cytoskeletal actin induced by inositol 1,4-bisphosphate in saponin-permeated pig platelets. Cell Biol Int 1994;18(8): 797-804
27. Ducibella T, Kurasawa S, Duffy P, et al. Regulation of the polyspermy block in the mouse egg: maturation-dependent differences in cortical granule exocytosis and zona pellucida modifications induced by inositol 1,4,5-trisphosphate and an activator of protein kinase C. Biol Reprod 1993; 48(6):1251-7
28. Orihuela PA, Parada-Bustamante A, Zuniga LM, et al. Inositol trisphosphate participates in an oestradiol nongenomic signalling pathway involved in accelerated oviductal transport in cycling rats. J Endocrinol 2006;188(3):579-88
29. Carlomagno G, et al. In: Monduzzi D, Controversies in Obstetrics and Gynecology & infertility 2011;23-6
30. Visser JA, de Jong FH, Laven JS, et al. Anti-mullerian hormone: a new marker for ovarian function. Reproduction 2006; 131(1):1-9
31. Papaleo E, Unfer V, Baillargeon JP, et al. Myo-inositol may improve oocyte quality in intracytoplasmic sperm injection cycles. A prospective, controlled, randomized trial. Fertil Steril 2009;91(5):1750-4
32. Lisi F, Carfagna P, Oliva MM, et al. Pretreatment with myo-inositol in non polycystic ovary syndrome patients undergoing multiple follicular stimulation for IVF: a pilot study. Reprod Biol Endocrinol 2012;10:52
33. Quirk JG Jr, Bleasdale JE. Myo-inositol homeostasis in the human fetus. Obstet Gynecol 1983;62(1):41-4
34. Chiu TT, Tam PP. A correlation of the outcome of clinical in vitro fertilization with the inositol content and embryotrophic properties of human serum. J Assist Reprod Genet 1992;9(6):524-30
35. Cavalli P, Tedoldi S, Riboli B. Inositol supplementation in pregnancies at risk of apparently folate-resistant NTDs. Birth Defects Res A Clin Mol Teratol 2008; 82(7):540-2
36. Greene ND, Copp AJ. Inositol prevents folate-resistant neural tube defects in the mouse. Nat Med 1997;3(1):60-6
37. Hendricks KA, Nuno OM, Suarez L, et al. Effects of hyperinsulinemia and obesity on risk of neural tube defects among Mexican Americans. Epidemiology 2001;12(6):630-5
38. Cavalli P, Copp AJ. Inositol and folate resistant neural tube defects. J Med Genet 2002;39(2):E5
39. Ehrmann DA, Barnes RB, Rosenfield RL, et al. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22(1):141-6
40. Legro RS. Insulin resistance in polycystic ovary syndrome: treating a phenotype without a genotype. Mol Cell Endocrinol 1998;145(1-2):103-10
41. Legro RS. Polycystic ovary syndrome. Phenotype to genotype. Endocrinol Metab Clin North Am 1999;28(2):379-96
42. Unfer V, Carlomagno G, Dante G, et al. Effects of myo-inositol in women with PCOS: a systematic review of randomized controlled trials. Gynecol Endocrinol 2012; 28(7):509-15
43. Genazzani AD, Battaglia C, Malavasi B, et al. Metformin administration modulates and restores luteinizing hormone spontaneous episodic secretion and ovarian function in nonobese patients with polycystic ovary syndrome. Fertil Steril 2004;81(1):114-19
44. Genazzani AD, Lanzoni C, Ricchieri F, et al. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Gynecol Endocrinol 2007;23(3):146-52
45. Genazzani AD, Lanzoni C, Ricchieri F, et al. Insulin mediators: structure and formation. Cold Spring Harb Symp Quant Biol 1988;53(Pt 2):965-71
46. Pak Y, Huang LC, Lilley KJ, et al. In vivo conversion of [3H]myoinositol to [3H] chiroinositol in rat tissues. J Biol Chem 1992;267(24):16904-10
47. Ortmeyer HK, Bodkin NL, Lilley K, et al. Chiroinositol deficiency and insulin resistance. I. Urinary excretion rate of chiroinositol is directly associated with insulin resistance in spontaneously diabetic rhesus monkeys. Endocrinology 1993; 132(2):640-5
48. Asplin I, Galasko G, Larner J. chiro-inositol deficiency and insulin resistance: a comparison of the chiro-inositol-and the myo-inositol-containing insulin mediators isolated from urine, hemodialysate, and muscle of control and type II diabetic subjects. Proc Natl Acad Sci USA 1993; 90(13):5924-8
49. Teede H, Deeks A, Moran L. Polycystic ovary syndrome: a complex condition with psychological, reproductive and metabolic manifestations that impacts on health across the lifespan. BMC Med 2010; 8(1):41
50. Baillargeon JP, Nestler JE. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab 2006;91(1):22-4
51. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome. N Engl J Med 1998;338(26): 1876-80
52. Hasegawa I, Murakawa H, Suzuki M, et al. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome. Fertil Steril 1999;71(2):323-7
53. Baillargeon JP, Diamanti-Kandarakis E, Ostlund RE Jr, et al. Altered D-chiro-inositol urinary clearance in women with polycystic ovary syndrome. Diabetes Care 2006;29(2):300-5
54. Nestler JE, Jakubowicz DJ, Reamer P, et al. Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. N Engl J Med 1999;340(17): 1314-20
55. Cheang KI, Baillargeon JP, Essah PA, et al. Insulin-stimulated release of D-chiroinositol-containing inositol phosphoglycan mediator correlates with insulin sensitivity in women with polycystic ovary syndrome. Metabolism 2008;57(10):1390-7
56. Isabella R, Raffone E. Does ovary need Dchiro-inositol? J Ovarian Res 2012;5(1):14
57. Chaudhury K, Narendra Babu K, Mamata Joshi V, et al. NMR-based metabolomics reveals differently expressed metabolites in follicular fluid of PCOS women: potential biomarkers for good quality oocyte? Hum Reprod 2011;i226-46
58. Pinero-Sagredo E, Nunes S, de Los Santos MJ, et al. NMR metabolic profile of human follicular fluid. NMR Biomed 2010;23(5):485-95
59. Arya BK, Haq AU, Chaudhury K. Oocyte quality reflected by follicular fluid analysis in poly cystic ovary syndrome (PCOS): A hypothesis based on intermediates of energy metabolism. Med Hypotheses 2012; 78(4):475-8
60. Ma X, Fan L, Meng Y, et al. Proteomic analysis of human ovaries from normal and polycystic ovarian syndrome. Mol Hum Reprod 2007;13(8):527-35
61. Unfer V, Carlomagno G, Papaleo E, et al. Hyperinsulinemia alters myoinositol to D-chiroinositol ratio in the follicular fluid of patients with PCOS. Reprod Sci 2014. [Epub ahead of print]
62. Matalliotakis I, Kourtis A, Koukoura O, Panidis D. Polycystic ovary syndrome: etiology and pathogenesis. Arch Gynecol Obstet 2006;4):187-97
63. Carlomagno G, Unfer V, Roseff S. The D-chiro-inositol paradox in the ovary. Fertil Steril 2011;95(8):2515-16
64. Heimark D, McAllister J, Larner J. Decreased myo-inositol to chiro-inositol (m/c) ratios and increased m/c epimerase activity in PCOS theca cells demonstrate increased insulin sensitivity compared to controls. Endocr J 2014;61(2):111-17
65. Unfer V, Carlomagno G, Papaleo E, et al. Hyperinsulinemia alters myo-inositol to d-chiro-inositol ratio in the follicular fluid of PCOS patients. Reprod Sci 2014. [Epub ahead of print]
66. Homburg R, Orvieto R, Bar-Hava I, Ben-Rafael Z. Serum levels of insulin-like growth factor-1, IGF binding protein-1 and insulin and the response to human menopausal gonadotrophins in women with polycystic ovary syndrome. Hum Reprod 1996;11(4):716-19
67. Ciotta L, Stracquadanio M, Pagano I, et al. Effects of myo-inositol supplementation on oocyte's quality in PCOS patients: a double blind trial. Eur Rev Med Pharmacol Sci 2011;15(5):509-14
68. Raffone E, Rizzo P, Benedetto V. Insulin sensitiser agents alone and in co-treatment with r-FSH for ovulation induction in PCOS women. Gynecol Endocrinol 2010; 26(4):275-80
69. Papaleo E, Unfer V, Baillargeon JP, et al. Myo-inositol in patients with polycystic ovary syndrome: a novel method for ovulation induction. Gynecol Endocrinol 2007;23(12):700-3
70. Genazzani AD, Lanzoni C, Ricchieri F, Jasonni VM. Myo-inositol administration positively affects hyperinsulinemia and hormonal parameters in overweight patients with polycystic ovary syndrome. Gynecol Endocrinol 2008;24(3):139-44
71. Morgante G, Orvieto R, Di Sabatino A, et al. The role of inositol supplementation in patients with polycystic ovary syndrome, with insulin resistance, undergoing the low-dose gonadotropin ovulation induction regimen. Fertil Steril 2011;95(8): 2642-4
72. Gerli S, Mignosa M, Di Renzo GC. Effects of inositol on ovarian function and metabolic factors in women with PCOS: a randomized double blind placebo-controlled trial. Eur Rev Med Pharmacol Sci 2003;7(6):151-9
73. Minozzi M, Costantino D, Guaraldi C, Unfer V. The effect of a combination therapy with myo-inositol and a combined oral contraceptive pill versus a combined oral contraceptive pill alone on metabolic, endocrine, and clinical parameters in polycystic ovary syndrome. Gynecol Endocrinol 2011;27(11): 920-4
74. Minozzi M, D'Andrea G, Unfer V. Treatment of hirsutism with myo-inositol: a prospective clinical study. Reprod Biomed Online 2008;17(4):579-82
75. Nordio M, Proietti E. The combined therapy with myo-inositol and D-chiro-inositol reduces the risk of metabolic disease in PCOS overweight patients compared to myo-inositol supplementation alone. Eur Rev Med Pharmacol Sci 2012;16(5): 575-81
76. Minozzi M, Nordio M, Pajalich R. The Combined therapy myo-inositol plus D-Chiro-inositol, in a physiological ratio, reduces the cardiovascular risk by improving the lipid profile in PCOS patients. Eur Rev Med Pharmacol Sci 2013; 17(4):537-40
77. Carlomagno G, Unfer V. Inositol safety: clinical evidences. Eur Rev Med Pharmacol Sci 2011;15:931-6
78. Corrado F, D'Anna R, Di Vieste G, et al. The effect of myoinositol supplementation on insulin resistance in patients with gestational diabetes. Diabet Med 2011; 28(8):972-5
79. D'Anna R, Di Benedetto V, Rizzo P, et al. Myo-inositol may prevent gestational diabetes in PCOS women. Gynecol Endocrinol 2012;28(6):440-2
80. Dunaif A, Segal KR, Shelley DR, et al. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes 1992;41(10): 1257-66
81. Nestler JE. Role of hyperinsulinemia in the pathogenesis of the polycystic ovary syndrome, and its clinical implications. Semin Reprod Endocrinol 1997;15(2): 111-22
82. Papaleo E, Unfer V, Baillargeon JP, Chiu TT. Contribution of myo-inositol to reproduction. Eur J Obstet Gynecol Reprod Biol 2009;147(2):120-3